$EPRX Archives - Vista Partners LLC | HomeVista Partners LLC

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. 19 hours ago 61Views 0Likes

Eupraxia Pharmaceuticals, Inc. (NASDAQ: EPRX) is quietly setting up one of the more intriguing biotech inflection points on Wall Street as it marches toward Phase 2b data for EP‑104GI in eosinophilic esophagitis (EoE) this December, with investors increasingly framing the “bar” in…

Cash, Catalysts and Credentials: Why Agenus and Eupraxia Are Starting to Screen In -( $AGEN $EPRX $XBI )

by John F. Heerdink, Jr. July 13, 2026 208Views 0Likes

Agenus Inc. (NASDAQ: AGEN) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) just offered Wall Street a reminder that in biotech, capital and human capital still set the tempo—one via an oversubscribed private placement, the other via a board refresh that reads…

Eupraxia’s Board Gets A Major Upgrade: Why EPRX Is Suddenly On Grown‑Up Biotech Lists -( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. July 7, 2026 253Views 0Likes

Eupraxia Pharmaceuticals Inc. (TSX: EPRX, NASDAQ: EPRX) is quietly assembling the kind of boardroom roster that makes Wall Street’s biotech specialists sit up, sharpen their models, and wonder if this “diffusion‑obsessed” Canadian upstart is planning something much bigger than a Phase 2 read‑out. A…

The Immune System Strikes Back: Why Biogen’s M&A Spree and Eupraxia’s Trial Progress Deserve a Place On Your Radar -( $APLS $BIIB $EPRX )

by John F. Heerdink, Jr. July 3, 2026 257Views 0Likes

Biogen Inc. (Nasdaq: BIIB) is quietly rewriting its own playbook, stitching together a next‑generation immunology franchise with a $1 billion bet on private upstart RayThera Inc. and a freshly closed $5.6 billion takeover of Apellis Pharmaceuticals Inc. (Nasdaq: APLS) that gives the…

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. May 18, 2026 400Views 0Likes

Eupraxia’s (NASDAQ: EPRX) current analyst chorus post their most recent First Quarter 2026 Financial Results report is now singing from the same hymn book: this is a late-stage GI platform story with cash in the bank, near-term catalysts, and price targets that…

Healthcare’s Quiet Rally: Incyte, Pfizer & Eupraxia Put Some Spring in Wall Street’s Step – ( $EPRX $INCY $PFE $XBI )

by John F. Heerdink, Jr. April 28, 2026 514Views 0Likes

Health care may not have the meme-stock glamour of AI chips, but this spring the sector is quietly reminding investors why 'boring' can be beautiful. A trio of updates from Incyte (INCY), Pfizer (PFE) and Eupraxia Pharmaceuticals (NASDA: EPRX) is painting a…

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 558Views 0Likes

Yes indeed, Eupraxia Pharmaceutical's (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time. A Chronic Disease Finally Meets a Long-Term Plan Eosinophilic…

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

by John F. Heerdink, Jr. March 2, 2026 554Views 0Likes

In a conference season dominated by mega-cap immunology franchises, Eupraxia Pharmaceuticals (NASDAQ: EPRX) quietly walked into AAAAI 2026 and walked out looking a lot less “micro‑cap” and a lot more “mispriced asset.” For investors willing to do more than skim the abstracts,…

Eupraxia’s Latest Raise: A Diffusphere-Fueled War Chest Aims at GI Disease -( $EPRX $IBB $XBI $SNY)

by John F. Heerdink, Jr. February 21, 2026 369Views 0Likes

In a market that has grown wary of “story stocks,” Eupraxia Pharmaceuticals (NASDAQ: EPRX) just delivered something refreshingly old-fashioned: a fully closed, upsized equity offering that actually funds a clinical plan rather than a marketing slogan. The clinical‑stage biotech, which trades on…

Eupraxia Pharmaceuticals: Injecting New Life Into EoE — One Microsphere at a Time -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. February 9, 2026 508Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) may still wear the “clinical-stage” name tag, but its stock has been behaving like it already found a seat at the grown‑ups’ table on Wall Street. Over the past year, shares have climbed roughly 160%, far outpacing the…

Tag: $EPRX

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

Cash, Catalysts and Credentials: Why Agenus and Eupraxia Are Starting to Screen In -( $AGEN $EPRX $XBI )

Eupraxia’s Board Gets A Major Upgrade: Why EPRX Is Suddenly On Grown‑Up Biotech Lists -( $EPRX $IBB $SNY $XBI )

The Immune System Strikes Back: Why Biogen’s M&A Spree and Eupraxia’s Trial Progress Deserve a Place On Your Radar -( $APLS $BIIB $EPRX )

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

Healthcare’s Quiet Rally: Incyte, Pfizer & Eupraxia Put Some Spring in Wall Street’s Step – ( $EPRX $INCY $PFE $XBI )

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

Eupraxia’s Latest Raise: A Diffusphere-Fueled War Chest Aims at GI Disease -( $EPRX $IBB $XBI $SNY)

Eupraxia Pharmaceuticals: Injecting New Life Into EoE — One Microsphere at a Time -( $EPRX $SNY $XBI )

Your Guide To Staying Informed In The Markets